Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Nikolaos Tentolouris"'
Autor:
Yasushi Fukushima, John B. Buse, Pernille Auerbach, Anette L. Søndergaard, Stanislava Macura, Nikolaos Tentolouris, Juan P. Frias, Ildiko Lingvay, Harpreet S. Bajaj, Tsvetalina Tankova
Publikováno v:
Diabetes. 70
Autor:
Yasushi Fukushima, Harpreet S. Bajaj, Tsvetalina Tankova, Nikolaos Tentolouris, Anette L. Søndergaard, John B. Buse, Juan P. Frias, Ildiko Lingvay, Pernille Auerbach, Stanislava Macura
Publikováno v:
Diabetes. 70
Once-weekly (OW) subcutaneous semaglutide 0.5 and 1.0 mg are approved maintenance doses for type 2 diabetes (T2D) treatment. We hypothesized that a higher dose of 2.0 mg would provide additional glycemic control with more patients achieving treatment
Publikováno v:
Diabetes. 69
Assessment of large fibre dysfunction is based on tuning fork (TF) for vibration perception and on monofilament (MF) for pressure sensation. Herein we examined the inter-rater variability of the MF and TF alongside with the VibraTip™ (VT), a new me
Autor:
Anastasios Tentolouris, Ioanna A. Anastasiou, Ioanna Eleftheriadou, Nikolaos Tentolouris, Iordanis Mourouzis, Andriani Angelopoulou, Ourania Kosta
Publikováno v:
Diabetes. 69
Bisphenol A (BPA) is an organic compound that is widely used in plastic products. It acts as an endocrine disruptor capable of mimicking or modifying the activity of endogenous hormones. Recent data have shown that exposure to BPA increases the risk
Autor:
Randi Grøn, Nikolaos Tentolouris, David C. Klonoff, Esteban Jódar, Natalie Halladin, Liana K. Billings
Publikováno v:
Diabetes. 67
In 5subjects with type 2 diabetes uncontrolled on metformin and basal insulin, the DUAL VII trial (NCT02420262) demonstrated that a once-daily injection of insulin degludec/liraglutide (IDegLira) was non-inferior to multiple injections of basal-bolus
Autor:
Elías Delgado, Arnaud Dauchy, Luiza Popescu, David Russell-Jones, Viera Donicova, Milan Kvapil, Nikolaos Tentolouris, Mireille Bonnemaire
Publikováno v:
Diabetes. 67
Many people with T2DM do not achieve HbA1c goals in clinical practice, owing in part to sub-optimal basal insulin titration. TAKE CONTROL, a 24-week, multicenter, randomized, open-label, parallel-group study, compared the efficacy and safety of a Gla
Autor:
Nikolaos Tentolouris, David Russell-Jones, Luiza Popescu, Mireille Bonnemaire, Melanie J. Davies, Jochen Sieber, Krzysztof Strojek, Masato Odawara, Emmanuelle Boelle-Le Corfec
Publikováno v:
Diabetes. 67
Empowering individuals to self-titrate their basal insulin may help to reduce rates of sub-optimal titration often observed in clinical practice and help more people achieve HbA1c goals. Here we compare the results from the recently completed TAKE CO
Autor:
Bernd Schultes, Thorsten Siegmund, Annunziata Lapolla, Nikolaos Tentolouris, Markus Eidenmueller, Andrei-Mircea Catarig, Michael L. Wolden, Rudolf Prager, Soren T. Knudsen
Publikováno v:
Diabetes. 67
EU-TREAT (NCT02662114), a European, multicenter, retrospective chart review study investigated the clinical impact of switching from any basal insulin to insulin degludec (degludec). This analysis aimed to evaluate the effectiveness of degludec after